DCK and acute myeloid leukemia: In vitro studies using drug‐selected AraC‐resistant AML and lymphoma cell models indicated that mutation or deficient expression and function of DCK could be acquired after receiving AraC therapy, resulting in the reduced cellular response to AraC and possible cross‐resistance to other nucleoside drugs like gemcitabine.33, 34, 35